Filed Pursuant to Rule 424(b)(3)
Registration No. 333-263456
PROSPECTUS SUPPLEMENT NO. 7
(To the Prospectus dated
May 19, 2022)
Up to 48,503,325 Shares of Common Stock
This prospectus supplement supplements the prospectus, dated May 19, 2022 (the “Prospectus”), which forms a part of our
registration statement on Form S-1 (No. 333-263456). This prospectus supplement is being filed to update and supplement the information in the Prospectus with certain
information contained in our Current Report on Form 8-K filed with the Securities and Exchange Commission on October 12, 2022 (the “Current Report”). Accordingly, we have attached the
Current Report to this prospectus supplement.
The Prospectus and this prospectus supplement relate to the offer and resale of up to
48,503,325 shares of our common stock, $0.0001 par value per share, by Tumim Stone Capital LLC (“Tumim”).
The shares of
common stock being offered by Tumim have been and may be issued pursuant to the common stock purchase agreement dated February 11, 2022 that we entered into with Tumim (the “Purchase Agreement”). We are not selling any
securities under this prospectus and will not receive any of the proceeds from the sale of our common stock by Tumim. However, we may receive up to $175.0 million in aggregate gross proceeds from sales of our common stock to Tumim that we may
make under the Purchase Agreement, from time to time after the date of this prospectus.
The common stock and Warrants are listed on the
New York Stock Exchange (“NYSE”) under the symbols “IRNT” and “IRNT.WS,” respectively. On October 11, 2022, the last reported sales price of our common stock on NYSE was $0.56 per share and the last reported
sales price of our Warrants was $0.0698 per warrant.
This prospectus supplement should be read in conjunction with the Prospectus,
including any amendments or supplements thereto, which is to be delivered with this prospectus supplement. This prospectus supplement is qualified by reference to the Prospectus, including any amendments or supplements thereto, except to the extent
that the information in this prospectus supplement updates and supersedes the information contained therein.
This prospectus supplement
is not complete without, and may not be delivered or utilized except in connection with, the Prospectus, including any amendments or supplements thereto.
We are an “emerging growth company” as defined under U.S. federal securities laws and, as such, have elected to comply with reduced
public company reporting requirements. The Prospectus complies with the requirements that apply to an issuer that is an emerging growth company.
Investing in
our securities involves a high degree of risk. You should review carefully the risks and uncertainties described in the section titled “Risk Factors” beginning on page 8 of the Prospectus and under similar headings in any amendments or
supplements to the Prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or
disapproved of these securities, or passed upon the accuracy or adequacy of this prospectus supplement or the Prospectus. Any representation to the contrary is a criminal offense.
Prospectus Supplement dated October 12, 2022